Ratings GENinCode Plc

Equities

GENI

GB00BL97B504

Delayed London S.E. Other stock markets 08:31:12 2024-05-22 am EDT			5-day change	1st Jan Change
8.18 ^GBX	-0.85%		-3.76%	+55.81%

Apr. 04	GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	CI
Mar. 21	GENinCode says ROCA recommended as ovarian cancer risk test in England	AN

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GENINCODE PLC	+55.81%	18.56M		-
BIOMÉRIEUX	-6.81%	12.1B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.93%	8.16B		B-
DIASORIN S.P.A.	+6.26%	5.78B		B
LANTHEUS HOLDINGS, INC.	+30.15%	5.59B		C
AUTOBIO DIAGNOSTICS CO., LTD.	-7.47%	4.23B		C
10X GENOMICS, INC.	-56.20%	2.87B		D+
ANDON HEALTH CO., LTD.	+12.56%	2.71B	-	-
VITROLIFE AB	-5.50%	2.35B		B-
MYRIAD GENETICS, INC.	+27.69%	2.21B		C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes